摘要
目的:探讨厄贝沙坦氢氯噻嗪片联合氨氯地平片治疗高血压的临床疗效与安全性。方法:将108例原发性高血压病患者,随机分成研究组与对照组,每组各54例。对照组患者采用厄贝沙坦氢氯噻嗪片治疗方案,研究组患者采用厄贝沙坦氢氯噻嗪片联合氨氯地平片治疗方案,以4周为1个疗程,分析两组患者的临床疗效与不良反应。结果:经过1个疗程的治疗,研究组患者的总有效率为90.74%,对照组患者的总有效率为75.93%,差异有统计学意义(P<0.05);研究组患者的不良反应与对照组无明显差异。结论:厄贝沙坦氢氯噻嗪片联合氨氯地平片方案治疗原发性高血压,效果良好。
Objective： To assess the clinical efficacy and safety of combination of irbesartan, hydrochlorothiazide and amlodipine in treating hypertension. Methods： 108 cases of primary hypertension were randomly divided into study group and control group, each 54 cases. On the basis of irbesartan and hydrochlorothiazide in the control group, the study group was added with amlodipine in a course of 4 weeks. Finally, the treatment outcome and side-effects were assessed after each treatment session between the two groups. Results： After treatment, the total effective rate was 90.74% in study group, si there was no significant dif gnificantly higher than 75.93% in control group （P〈0.05）. However, ference in occurrence of adverse reactions between the two groups. Conclusion： Irbesartan and hydrochlorothiazide combined with amlodipine has a good effect in treatment of hypertension, with less adverse reaction.
出处
《华夏医学》
CAS
2015年第1期47-49,共3页
Acta Medicinae Sinica
关键词
厄贝沙坦氢氯噻嗪
氨氯地平
高血压
临床疗效
安全性
Key words.irbesartan and hydrochlorothiazide
amlodipine
hypertension
clinical efficacy
safety
